PET Imaging for Response Assessment in Lymphoma: Potential and Limitations

Heiko Schöder, Craig Moskowitz

Research output: Contribution to journalReview article

39 Citations (Scopus)

Abstract

Fluorodeoxyglucose positron emission tomography (FDG-PET) is now considered the most accurate tool for the assessment of treatment response and prognosis in patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma. This article discusses the potential and limitations of FDG-PET for response assessment in malignant lymphoma during chemotherapy (interim PET) and at the end of chemotherapy. Interim PET is used to predict the likelihood for a complete response at the end of such therapy. End-of-treatment PET aims to establish the completeness of response or the presence of residual viable tumor tissue. Until the results of ongoing clinical trials emerge over the next 5 years, interim PET should be considered investigational and should not be used for patient management outside of study protocols.

Original languageEnglish (US)
Pages (from-to)225-241
Number of pages17
JournalRadiologic Clinics of North America
Volume46
Issue number2
DOIs
StatePublished - Mar 1 2008
Externally publishedYes

Fingerprint

Lymphoma
Positron-Emission Tomography
Drug Therapy
Residual Neoplasm
Hodgkin Disease
Non-Hodgkin's Lymphoma
Therapeutics
Clinical Trials

Keywords

  • FDG
  • Lymphoma
  • PET
  • PET-CT
  • Response

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

PET Imaging for Response Assessment in Lymphoma : Potential and Limitations. / Schöder, Heiko; Moskowitz, Craig.

In: Radiologic Clinics of North America, Vol. 46, No. 2, 01.03.2008, p. 225-241.

Research output: Contribution to journalReview article

@article{8442d9c0ef8544ce91e2ecc55936cf4d,
title = "PET Imaging for Response Assessment in Lymphoma: Potential and Limitations",
abstract = "Fluorodeoxyglucose positron emission tomography (FDG-PET) is now considered the most accurate tool for the assessment of treatment response and prognosis in patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma. This article discusses the potential and limitations of FDG-PET for response assessment in malignant lymphoma during chemotherapy (interim PET) and at the end of chemotherapy. Interim PET is used to predict the likelihood for a complete response at the end of such therapy. End-of-treatment PET aims to establish the completeness of response or the presence of residual viable tumor tissue. Until the results of ongoing clinical trials emerge over the next 5 years, interim PET should be considered investigational and should not be used for patient management outside of study protocols.",
keywords = "FDG, Lymphoma, PET, PET-CT, Response",
author = "Heiko Sch{\"o}der and Craig Moskowitz",
year = "2008",
month = "3",
day = "1",
doi = "10.1016/j.rcl.2008.04.002",
language = "English (US)",
volume = "46",
pages = "225--241",
journal = "Radiologic Clinics of North America",
issn = "0033-8389",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - PET Imaging for Response Assessment in Lymphoma

T2 - Potential and Limitations

AU - Schöder, Heiko

AU - Moskowitz, Craig

PY - 2008/3/1

Y1 - 2008/3/1

N2 - Fluorodeoxyglucose positron emission tomography (FDG-PET) is now considered the most accurate tool for the assessment of treatment response and prognosis in patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma. This article discusses the potential and limitations of FDG-PET for response assessment in malignant lymphoma during chemotherapy (interim PET) and at the end of chemotherapy. Interim PET is used to predict the likelihood for a complete response at the end of such therapy. End-of-treatment PET aims to establish the completeness of response or the presence of residual viable tumor tissue. Until the results of ongoing clinical trials emerge over the next 5 years, interim PET should be considered investigational and should not be used for patient management outside of study protocols.

AB - Fluorodeoxyglucose positron emission tomography (FDG-PET) is now considered the most accurate tool for the assessment of treatment response and prognosis in patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma. This article discusses the potential and limitations of FDG-PET for response assessment in malignant lymphoma during chemotherapy (interim PET) and at the end of chemotherapy. Interim PET is used to predict the likelihood for a complete response at the end of such therapy. End-of-treatment PET aims to establish the completeness of response or the presence of residual viable tumor tissue. Until the results of ongoing clinical trials emerge over the next 5 years, interim PET should be considered investigational and should not be used for patient management outside of study protocols.

KW - FDG

KW - Lymphoma

KW - PET

KW - PET-CT

KW - Response

UR - http://www.scopus.com/inward/record.url?scp=46449129657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46449129657&partnerID=8YFLogxK

U2 - 10.1016/j.rcl.2008.04.002

DO - 10.1016/j.rcl.2008.04.002

M3 - Review article

C2 - 18619378

AN - SCOPUS:46449129657

VL - 46

SP - 225

EP - 241

JO - Radiologic Clinics of North America

JF - Radiologic Clinics of North America

SN - 0033-8389

IS - 2

ER -